Test Price
2,800 AED✅ Home Collection Available
MYO7A Gene (Autosomal Dominant Deafness Type 11) Genetic Test in UAE – 2800 AED – DHA Licensed
Executive Summary & Core Metrics
- ✓ Diagnostic Accuracy: >99.9% analytical sensitivity via ISO‑certified NGS platform.
- ✓ Sample Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM–11 PM).
- ✓ Post‑Test Support: Telephonic genetic counselling session included for result interpretation.
- ✓ Insurance Verification: Direct WhatsApp confirmation at +971 54 548 8731.
Test Overview & Methodology
The MYO7A gene NGS test detects pathogenic variants causing autosomal dominant deafness type 11 (DFNA11) with high accuracy. This comprehensive analysis uses Next‑Generation Sequencing (NGS) technology at our ISO‑certified laboratory in Dubai Healthcare City.
| Feature | Our NGS Test | Traditional Sanger Sequencing |
|---|---|---|
| Analytical Sensitivity | >99.9% (complete gene coverage) | ~95% (exon‑by‑exon) |
| Variant Detection | SNVs, indels, copy number variants | SNVs and small indels only |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Pre‑test Genetic Counseling | Included (pedigree charting) | Often not provided |
Physician Insight & Safety Protocols
Clinical Note – Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
As a clinical geneticist, I understand the emotional weight of hereditary hearing loss. This NGS assay offers definitive molecular diagnosis for DFNA11, but a negative result cannot exclude other genetic or non‑genetic causes. Continuous audiological follow‑up and a multidisciplinary approach remain vital.
Medication Advisory
Medication Warning: Do not discontinue any prescribed medication without consulting your physician. Genetic test results should never replace clinical management.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Red Flags
- ⚠ Minors: Mandatory parental/legal guardian consent under Federal Decree‑Law No. 4 of 2016 on Medical Liability. Sample collection from children requires a pediatric phlebotomist.
- ⚠ Acute Conditions: Patients with fever >38.5°C or active infection should postpone testing until recovery.
- ⚠ Emergency Red Flags (seek immediate medical care): Sudden sensorineural hearing loss, acute vertigo, otalgia, or facial nerve palsy. This genetic test is not for emergency diagnosis.
Patient FAQ & Clinical Guidance
1. What is the MYO7A gene and its role in autosomal dominant deafness?
The MYO7A gene encodes myosin VIIA, a motor protein critical for hair cell mechanotransduction in the inner ear. Pathogenic variants cause progressive, autosomal dominant sensorineural hearing loss type 11 (DFNA11).
2. How is this test performed and what sample is required?
A simple venous blood draw (3–5 ml) provides sufficient DNA for our high‑coverage NGS analysis. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection is available daily from 8 AM to 11 PM across the UAE.
3. What is the turnaround time and cost for this test in the UAE?
Results are delivered within 3 to 4 weeks at a cost of 2,800 AED, including pre‑test genetic counseling and a post‑result telephonic interpretation session with our clinical genetics team.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Governance
- All personal data and genetic test results are processed in compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Patient consent and clinical safety follow Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | MYO7A Gene Sequencing (Autosomal Dominant Deafness Type 11 – DFNA11) – NGS |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 ml) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection Available Daily 8 AM–11 PM |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full gene coverage with >99.9% analytical sensitivity |
| ICD‑10‑CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 94122-3 (MYO7A gene mutation analysis in blood by NGS) |
| DHA Facility License & Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians